Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma

NCT01615029 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Part 1 (Dose Escalation): Daratumumab
DRUG: Part 2 (Dose Expansion): Daratumumab
DRUG: Lenalidomide
DRUG: Dexamethasone

Sponsor

Janssen Research & Development, LLC